MAP Pharmaceuticals Inc.

Mountain View, Calif. • 650-386-3100 •

Exchange and Ticker: Nasdaq: MAPP

Filing Range: 5M shares @ $14.00 to $16.00

Offering Price: $12.00

Close on First Day: $13.35

Offering Size: $60M

Shares Outstanding: 19,272,409

Underwriters: Merrill Lynch/ Morgan Stanley

Co-managers: Deutsche Bank Securities Corp.

Company Counsel: Latham & Watkins

Manager Counsel: Heller Ehrman LLP

Auditor: Pricewaterhouse Coopers LLP

Market Capitalization on 10/31/07: $267.50M

Close price at current month end: $13.88


Develops inhaled drug products. The company’s therapies and inhalation delivery platforms treat a spectrum of respiratory and systemic diseases. MAP’s lead product is a proprietary formulation of budesonide for the treatment of pediatric asthma. Competitors include Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd. and GlaxoSmithKline.


Aisling Capital, Alexandria Real Estate Equities, Bain Capital, Bay City Capital, D.E. Shaw Technology Ventures, Pequot Capital Management Inc., Skyline Ventures

Source: Thomson Financial